On March 2, 2017, the Securities and Exchange Commission announced that AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a medical device company based in Orlando, Florida, announced that it has agreed to pay $45 million to settle regulatory charges related to its use of opioid analgesics.  The SEC's complaint, filed in the U.S. District Court for the District of Florida, alleges that AcelRx violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  The SEC's complaint charges AcelRx with violating Section 17(a) of the Securities Act and Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and charges AcelRx with violating the antifraud provisions of Section 10(b) of the Exchange Act.  Without admitting or denying the allegations in the SEC's complaint, AcelRx has agreed to settle the charges without admitting or denying the allegations in its SEC filings.  The settlement is subject to court approval.  The SEC's investigation was conducted by David Rymas of the Boston Regional Office and was supervised by Marc Blau.  The litigation will be led by Mr. Blau.  The SEC appreciates the assistance of the U.S. Attorney's Office for the District of Florida, the Federal Bureau of Investigation, and the U.S. Secret Service.  The SEC's Office of Investor Education and Advocacy has issued anÂ Investor AlertÂ to encourage investors to check the background of anyone selling or offering them an investment using the free and simple search tool onÂ Investor.gov.